GeoVax Set to Unveil Fourth Quarter and Full Year 2024 Financial Results

Biotechnology company GeoVax Labs, Inc. will report its financial results for the fourth quarter and full year of 2024 on March 27, 2025, followed by a conference call to discuss the company's performance and strategic initiatives. The announcement underscores the company's continued progress in developing innovative vaccines and therapeutic treatments for critical medical challenges.

The conference call, scheduled for 4:30 p.m. ET, will provide investors and stakeholders with insights into the company's lead clinical programs, particularly its COVID-19 vaccine candidate GEO-CM04S1 and oncology treatment Gedeptin®. The company recently received a BARDA-funded contract to sponsor a significant 10,000-participant Phase 2b clinical trial evaluating GEO-CM04S1's efficacy compared to existing COVID-19 vaccines.

GeoVax's COVID-19 vaccine program is currently conducting three Phase 2 clinical trials targeting specific patient populations. These trials aim to assess the vaccine's effectiveness as a primary vaccine for immunocompromised patients, a booster for chronic lymphocytic leukemia patients, and a more robust booster for individuals who previously received mRNA vaccines.

In the oncology sector, the company is advancing its Gedeptin® therapy, which recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. A planned Phase 2 clinical trial will evaluate Gedeptin® in combination with an immune checkpoint inhibitor for first recurrent head and neck cancer patients.

The upcoming financial report and conference call represent an opportunity for GeoVax to demonstrate its continued commitment to developing innovative medical solutions and potentially addressing critical unmet medical needs in COVID-19 vaccination and cancer treatment.